EP4401803A1 - Population de surfaces avec des cellules biologiques - Google Patents

Population de surfaces avec des cellules biologiques

Info

Publication number
EP4401803A1
EP4401803A1 EP22768269.7A EP22768269A EP4401803A1 EP 4401803 A1 EP4401803 A1 EP 4401803A1 EP 22768269 A EP22768269 A EP 22768269A EP 4401803 A1 EP4401803 A1 EP 4401803A1
Authority
EP
European Patent Office
Prior art keywords
cells
biological cells
hfm
azide
dbco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22768269.7A
Other languages
German (de)
English (en)
Inventor
Meltem AVCI-ADALI
Denis Canjuga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Universitaetsklinikum Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Universitaetsklinikum Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen, Universitaetsklinikum Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of EP4401803A1 publication Critical patent/EP4401803A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment

Definitions

  • the present invention relates to a method for producing a surface that can be colonized with biological cells, a device with a surface that can be colonized with biological cells, and a method for colonizing a surface with biological cells.
  • COPD chronic obstructive pulmonary disease
  • extracorporeal membrane oxygenation is performed by continuously pumping the patient's blood through a gas-permeable membrane oxygenator (artificial lung) that mimics the gas exchange process of the lungs.
  • Standard blood oxygenators consist of bundles of microporous hollow fiber membranes (HFM), most commonly made of polypropylene (PP) or polymethylpentene (PMP), with a large surface area ( ⁇ 2 m 2 ) to achieve clinically required O2 and CO2 transport rates.
  • HFM microporous hollow fiber membranes
  • PP polypropylene
  • PMP polymethylpentene
  • heparin [Pappalardo, F., et al., Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion, 2009. 24(2): pp. 135-137] or poly-2-methoxyethyl acrylate (PMEA) [Eisses, MJ, et al., Effect of polymer coating (poly 2-methoxyethyl acrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children. J Cardiothorac Vase Anesth, 2007. 21(1): pp. 28-34.].
  • the coating of surfaces with polydopamine is known, for example, from CN 110545754, and the coating with polymers from US Pat. No. 6,309,660. However, both approaches have not proven themselves in practice.
  • heparin The most common approach is to coat the surfaces with heparin, as described for example in WO 2020/190214.
  • the heparin can detach from the surface and lead to the formation of thrombi.
  • long-term exposure to heparin carries the risk that the patient will develop heparin-induced thrombocytopenia (HIT).
  • HIT heparin-induced thrombocytopenia
  • PF4 platelet factor 4
  • cRGD Moller, L, et al., Towards a biocompatible artificial lung: Covalent functionalization of poly(4-methylpent-1-ene) (TPX) with cRGD pentapeptide. Beilstein Journal of Organic Chemistry, 2013. 9: pp. 270-277] or fibronectin [Cornelissen, CG, et al., Fibronectin coating of oxygenator membranes enhances endothelial cell attachment. Biomed Eng Online, 2013. 12:p.7] to aid in endothelialization.
  • a method for producing a surface that can be colonized with biological cells in which the disadvantages of the prior art are avoided or at least reduced.
  • a surface should be provided that can be populated with biological cells in such a way that a high degree of biocompatibility is achieved.
  • This object is achieved by a method for producing a surface that can be colonized with biological cells, which has the following steps:
  • a “surface” includes any area that is to be populated with biological cells, for example endothelial cells. This includes, but is not limited to, surfaces of medical products or medical devices, such as artificial lungs of oxygenators, e.g. the walls of membranes where gas exchange takes place. Plastic or metal surfaces are also included according to the invention.
  • biological cells means any type of cell, such as endothelial cells, but also stem cells, including mesenchymal stem cells, and progenitor cells thereof or cells derived therefrom, such as endothelial progenitor cells (EPCs) or endothelial cells derived from induced pluripotent stem cells (“iPSC-derived endothelial cells”).
  • EPCs endothelial progenitor cells
  • iPSC-derived endothelial cells induced pluripotent stem cells
  • “Silanization” in step 2 of the method according to the invention is understood as meaning the chemical attachment of a silane compound to the surface. This can be done, for example, but not exclusively, by reacting the free hydroxyl groups with 3-aminopropyltriethoxysilane (APTES).
  • APTES 3-aminopropyltriethoxysilane
  • step 3 of the method of the invention the reactant capable of reacting in a copper-free click reaction with azides, such as, but not limited to, dibenzocyclooctyne (DBCO), is conjugated to the silanized surface using methods known to those skilled in the art.
  • azides such as, but not limited to, dibenzocyclooctyne (DBCO)
  • a “click reaction”, also synonymously referred to as “click chemistry”, means a reaction between azide and alkyne to provide a 1,5-disubstituted 1,2,3-triazole. According to the invention, this takes place without the use of copper or other cytotoxic catalysts under physiological conditions, e.g. in the cell culture medium. This represents a departure from the "click responses" used in the prior art.
  • Cu-AAC copper-catalyzed azide-alkyne cycloadditions
  • the surfaces produced according to the invention are now capable of reacting with azides in a copper-free click reaction and thereby covalently binding structures which expose azide groups (N3) to the surface.
  • azide groups N3
  • endothelial cells can be functionalized in such a way that they have glycoproteins with azide groups on their surfaces. These groups can be covalently conjugated to the reactant such as DBCO in a copper-free click reaction.
  • the method according to the invention thus provides surfaces which can be colonized efficiently and in a targeted manner with azide-modified biological cells. Because this reaction is very specific, only those biological cells that expose azide groups are bound to the surface. This prevents the non-specific binding of undesired cell populations.
  • the method according to the invention can also be used to bind the patient's own endothelial progenitor cells (EPCs) or endothelial cells which are derived from induced pluripotent stem cells (“iPSC-derived endothelial cells”) to desired surfaces of blood-contacting materials.
  • EPCs endothelial progenitor cells
  • iPSC-derived endothelial cells endothelial cells which are derived from induced pluripotent stem cells
  • the reactant of step 3 is selected from the group consisting of: cycloalkyne, cycloalkyne ester, phosphine and phosphine ester.
  • This measure has the advantage that those reactants are used which are suitable for being able to react with azides in a copper-free click reaction and are therefore particularly functional according to the invention.
  • phosphine groups react with the azide groups in a so-called Staudinger reaction.
  • This reaction shows slow reaction kinetics of about 10' 3 M' 1 s' 1 .
  • Cycloalkynes react with the azide groups in a so-called 'strain-promoted azide-alkyne cycloaddition reaction' (SPAAC).
  • SPAAC 'strain-promoted azide-alkyne cycloaddition reaction'
  • the second-order reaction has a moderate rate constant of 10' 2 — 1 M' 1 s' 1 .
  • the cycloalkyne dibenzocyclooctyne (DBCO) and/or the cycloalkyne ester DBCO-PEG4-NHS ester is used as the reactant.
  • DBCO cycloalkyne dibenzocyclooctyne
  • DBCO-PEG4-NHS ester is used as the reactant.
  • step 1 the surface containing hydroxyl groups is provided by oxygen plasma treatment of a surface.
  • This measure has the advantage that a method is used that is particularly suitable for generating hydroxyl groups on the surface.
  • the surface is one of a medical device, preferably selected from the group consisting of: artificial lung, oxygenator, artificial kidney, prosthesis, vascular prosthesis, stent, artificial heart.
  • This measure has the advantage that the method is used where the colonization of surfaces with biological cells for the functionality and Biocompatibility of the devices is particularly important. When used in patients, it can thus be prevented that the device is recognized as "foreign".
  • the surface is a surface of a hollow fiber membrane (HFM), preferably a polymethylpentene or polypropylene HFM.
  • HFM hollow fiber membrane
  • This measure has the advantage that the method is used for blood-contacting surfaces that are particularly relevant in practice, which are used, for example, in oxygenators.
  • the biological cells are endothelial cells.
  • the biological cells have azide groups (-N3) on their surface.
  • Another object of the invention relates to a device with a surface that can be colonized with biological cells, preferably an artificial lung, an oxygenator, an artificial kidney, a prosthesis, a vascular prosthesis, a stent, an artificial heart or a hollow fiber membrane (HFM) such as a polymethylpentene or polypropylene HFM, wherein the surface has a reactant that reacts with azides in a copper-free click reaction.
  • biological cells preferably an artificial lung, an oxygenator, an artificial kidney, a prosthesis, a vascular prosthesis, a stent, an artificial heart or a hollow fiber membrane (HFM) such as a polymethylpentene or polypropylene HFM, wherein the surface has a reactant that reacts with azides in a copper-free click reaction.
  • HFM hollow fiber membrane
  • the surface which can be colonized with biological cells was preferably obtained using the method according to the invention.
  • the features, properties, advantages and embodiments of the manufacturing method according to the invention also apply in
  • Another object of the present invention relates to a method for colonizing a surface with biological cells, which has the following steps:
  • the surface having a reactant reacting with azides in a copper-free click reaction was obtained using the production method according to the invention.
  • the biological cells which have azide groups (-N3) on their surface were obtained by incubating biological cells with an azide sugar which is preferably selected from the group consisting of: Ac4ManNAz (N- azidoacetylmannosamine-tetraacylated), N-azidoacetylglucosamine-tetraacylated (Ac4GlcNAz), N-azidoacetylgalactosamine-tetraacylated (Ac4GalNAz), and other azide-functionalized glycoconjugates.
  • an azide sugar which is preferably selected from the group consisting of: Ac4ManNAz (N- azidoacetylmannosamine-tetraacylated), N-azidoacetylglucosamine-tetraacylated (Ac4GlcNAz), N-azidoacetylgalactosamine-tetraacylated (Ac4GalNAz), and other azide-functionalized
  • nucleic acid By this measure, biological cells are obtained in an advantageous manner, which expose azide groups (-N3) on their surface.
  • the azide sugars specified are particularly suitable for the functionalization of the cells. Like their natural analogues, the azide sugars are taken up into the cells and incorporated into glycoproteins. This causes the cells to have glycoproteins on the cell surface that are provided with azide groups (-N3). These groups can be covalently conjugated to the surface using click chemistry.
  • Incubating the modified cells with the modified HFMs results in a bio-orthogonal reaction, the alkyne group of the reactant or DBCO reacts with the azide on the surface of the cells. This happens very specifically, so only modified cells with azide molecules can bind to the reactants on the membrane. Binding of the cells to the membrane and further incubation in cell culture medium leads to proliferation and ultimately colonization of the membrane with a confluent monolayer of cells.
  • the biological cells are endothelial cells.
  • the surfaces are populated with cells that are of particular importance for the functionality of important medical surfaces or devices.
  • Particularly suitable are primary endothelial cells isolated from umbilical cord blood, so-called Human Umbilical Vein Endothelial Celis (HUVECs), which are cultivated in VascuLife® EnGS Endothelial Medium Complete Kit until they are endothelialized.
  • HUVECs Human Umbilical Vein Endothelial Celis
  • colonization with the endothelial cells can take place in EGM-2 Endothelial Cell Growth Medium-2 BulletKit.
  • Polymethylpentene HFMs (PMP, OXYPLUS, 3M Membrana, Wuppertal, Germany), APTES, methanol, toluene (Sigma-Aldrich, Darmstadt), DBCO-PEG4-NHS ester (Jena Bioscience, Jena, Germany), Dulbecco's phosphate-buffered saline (DPBS), (Invitrogen), N-azidoacetylmannosamine-tetraacylated (Ac4ManNAz, Sigma Aldrich, Germany), DMSO (Sigma-Aldrich).
  • Fig. 1 Schematic representation of the functionalization of the PMP hollow fiber membranes (HFMs).
  • HFMs PMP hollow fiber membranes
  • Fig.2 Detection of the generated functional groups on PMP hollow fiber membranes (HFMs).
  • Fig. 3 Result of the SEM analysis. There are no visual differences on the
  • FIG. 6 Metabolic labeling of HUVECs with Ac4ManNAz and cell viability analysis. 2x10 5 HUVECs were incubated for 48 h with and without 50 pM Ac4ManNAz.
  • B) Cells were incubated for 1 hour with 5 pM DBCO-Sulfo-Cy3 and, after washing with DPBS, flow cytometric analyzes were performed. Results are presented as mean ⁇ SD (n 3).
  • Fig. 8 Analysis of the response of the endothelialized surface to an inflammatory stimulus using qRT-PCR.
  • Endothelialized HFM were treated with 50 ng/ml TNF- ⁇ and the expression of adhesion molecules (E-selectin, VCAM-1 and ICAM-1) was determined by qRT-PCR.
  • TAT thrombin-antithrombin III complex
  • sC5b-9 complement system
  • PMN- Elastase inflammation
  • HIVECs Human Umbilical Vein Endothelial Cells
  • HUVECs (ATCC®, Manassas, USA) were seeded in T75 cell culture flasks coated with 0.1% gelatin and cultured at 37°C and 5% CO2 in Vasculife® EnGS EC culture medium (CellSystems, Troisdorf, Germany) with VascuLife EnGS LifeFactors Kit, 50 mg/ml gentamicin and 0.05 mg/ml amphotericin B (Thermo Fisher Scientific, Waltham, USA). The medium was changed every 3 days. After reaching 80% confluency, the cells were detached with trypsin/EDTA (0.04%/0.03%, PromoCell, Heidelberg, Germany).
  • the surface of polymethylpentene HFMs (PMP, OXYPLUS, 3M Membrana, Wuppertal, Germany) was coated in a three-stage process ( Figure 1). First the surface was treated with 02 plasma and in the second step the silanization was carried out. In the third step, dibenzylcyclooctyne-PEG4-NHS-ester (DBCO-PEG4-NHS-ester) was conjugated to the silanized surface.
  • DBCO-PEG4-NHS-ester dibenzylcyclooctyne-PEG4-NHS-ester
  • PMP membranes were cut to a size of 3 x 3 cm and treated with 02 plasma (Denta Pias®, Diener electronic, Ebhausen, Germany) for 30 min at a pressure of 0.3 mbar ( ⁇ 0.20 mbar ) and an output of 80% ( ⁇ 5%) hydroxyl groups.
  • the HFMs were then incubated for 30 minutes in toluene (Sigma-Aldrich, Darmstadt, Germany) with 2% (3-aminopropyl)triethoxysilane (APTES, Sigma-Aldrich) on a shaker at 20 rpm.
  • the membranes were then sonicated in 100% toluene, 50% toluene/50% methanol, and 100% methanol for 2 minutes each to remove unbound or weakly bound APTES. After drying, the membranes were soaked in 400 M DBCO-PEG4-NHS-ester (Jena Bioscience, Jena, Germany) with Dulbecco's phosphate-buffered saline for 30 minutes (DPBS) (Invitrogen, Carlsbad, USA) to introduce cyclooctyne groups and washed three times with fresh DPBS.
  • DPBS Dulbecco's phosphate-buffered saline for 30 minutes
  • the membranes were incubated for 5 hours in 0.5 mM methyl orange (Sigma-Aldrich, Darmstadt, Germany) at 37°C on a shaker, followed by washing three times with 1 mM HCl -Solution. Desorption of bound methyl orange from the HFM surface was performed with 0.4 mL of a 1 mM NaOH solution overnight at 37°C on a shaker. For detection of methyl orange, 100 ⁇ l of the desorption solution was placed in triplicate in a 96-well plate. The absorbance was measured at 465 nm with a microplate reader (Eon Synergy 2, Bio Tek Instruments Inc., Winooski USA).
  • the HFM in DPBS without Ca 2+ /Mg 2+ were incubated for 1 hour with 80 pg/ml Cy3-azide (Sigma-Aldrich) to convert the Cy3-azide bind to the DBCO-functionalized HFM surface.
  • the HFMs were then washed five times with 100% ethanol and the staining of the membranes was detected using fluorescence microscopy (Axiovert 135, Carl Zeiss AG, Oberkochen, Germany).
  • the fluorescence intensity on the membranes was quantified using a microplate reader (Mithras 940, Berthold Technologies, Bad Wildbad, Germany) at an excitation wavelength of 500 nm and an emission wavelength of 600 nm. HFM with no treatment and with APTES treatment only were used as controls.
  • HUVECs 1 .4 Metabolic labeling of HUVECs with azide groups and detection of the azide label
  • 2 x 10 5 HUVECs were seeded per well of a 6-well plate and tetraacylated with or without 50 pM N-azidoacetylmannosamine (Ac4ManNAz, Sigma Aldrich) in 2 ml medium for Treated with 5% CO2 at 37°C for 48 h.
  • the cells were washed with DPBS without Ca 2+ /Mg 2+ and with 5 pM DBCO-Sulfo-Cy3 (Jena Bioscience, Germany) in DPBS with Ca 2+ /Mg 2+ for 1 h at 37° C and 5% CO2.
  • the cells were washed three times with 10 ml DPBS, detached with trypsin/EDTA (0.04%/0.03%) and centrifuged at 300 ⁇ g for 5 minutes.
  • the cell pellet was resuspended in 0.5 ml DPBS and the Cy3 labeling of 10,000 cells was analyzed by flow cytometry (FACS SCAN, BD, Heidelberg, Germany).
  • HUVECs The influence of metabolic labeling on the viability of HUVECs was examined 48 hours after labeling with 50 pM Ac4ManNAz using the PrestoBlue assay (Invitrogen, Carlsbad, USA). For this purpose, 500 pL 1 ⁇ Presto Blue cell viability reagent were added per well of a 6-well plate and incubated at 37° C. for 1.5 h. The fluorescence intensity of 100 pL of supernatant was measured in triplicate at an excitation wavelength of 530 nm and an emission wavelength of 600 nm using a multimode microplate reader (Mithras LB 940, Berthold Technologies, Bad Wildbad, Germany).
  • DBCO-coated and uncoated PMP membranes (3 x 3 cm) were incubated with 5.2 x 10 6 Ac4ManNAz-labeled HUVECs in 13 ml of EGMTM-2 endothelial cell growth medium BulletKitTM (Lonza, Basel, Switzerland). Incubation was carried out for 24 hours at 10 rpm with a rotator (Phoenix Instrument, Garbsen, Germany) in one humidified incubator with 5% CO2 at 37°C. After the rotary incubation, the membranes were placed in each well of a 6-well plate and further incubated for 1 or 5 days under static conditions.
  • the HLIVECs attached to the membranes were stained with 250 ng/mL calcein acetoxymethyl ester (Calcein-AM; Invitrogen) for 10 minutes at 37°C.
  • the stained cells were detected using fluorescence microscopy (Axio 135, Carl Zeiss AG, Oberkochen, Germany).
  • fluorescence signal on the surface of the HFMs before and after calcein-AM staining was detected at an excitation wavelength of 494 nm and an emission wavelength of 517 nm using a multimode microplate reader (Mithras LB 940, Berthold Technologies).
  • the formation of a confluent endothelial cell monolayer and the presence of cell-cell contacts were detected by staining the cells with an anti-human VE-cadherin antibody.
  • the membranes coated with DBCO-PEG4-NHS ester and endothelialized were washed with DPBS and fixed in 4% paraformaldehyde (v/v) for 10 minutes at RT. After washing with DPBS, blocking was performed with Tris-buffered saline (50 mM Tris base, 150 mM sodium chloride, pH 7.5) containing 5% goat serum (Thermo Fisher Scientific, Waltham, USA) for 30 minutes at RT.
  • the membranes were washed with DPBS and with the primary antibody mouse anti-human VE-cadherin (CD144 (16B1), eBioscience, Invitrogen, USA) diluted 1:100 in DPBS with 1% bovine serum albumin (BSA) for 1 h at RT incubated. The membranes were then washed three times with DPBS and incubated with 1:400 diluted goat anti-mouse IgG (H+L) cross-adsorbed secondary antibody (ThermoFisher, USA) labeled with Alexa Fluor 488 (ThermoFisher, USA) for 1 h in PBS with 1% BSA .
  • the cell nuclei were stained for 5 minutes with DAPI (Sigma Aldrich, Darmstadt, Germany) diluted 1:2000 in DPBS. As a negative control, the membranes were also incubated with an isotype control antibody. The stained cells were detected using fluorescence microscopy (Axio 135, Carl Zeiss AG, Aoberkochen, Germany). 1 .8 Reactivity of the endothelium to HFMs to the inflammatory stimulus
  • Endothelialized HFMs were incubated for 4 hours without or with 50 ng/mL tumor necrosis factor ⁇ (TNF- ⁇ , Sigma-Aldrich) in EGMTM-2 endothelial cell growth medium without hydrocortisone. After incubation, the HFMs were washed twice with DPBS and total RNA isolated. Expression of the activation markers, endothelial leukocyte adhesion molecule 1 (E-selectin), vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), was detected by qRT-PCR. The mRNA levels were normalized to the GAPDH mRNA levels and the results were presented relative to the expression levels in endothelialized HFM without TNF- ⁇ stimulation.
  • TNF- ⁇ tumor necrosis factor ⁇
  • RNA was isolated with the Aurum Total RNA Mini Kit (Bio-Rad, Kunststoff, Germany) according to the manufacturer's instructions. 300 ng of RNA was reverse transcribed into DNA copies (cDNA) using the iScript Kit (Bio-Rad). The transcripts were amplified using the primers listed in Table 1 in a final concentration of 300 nM under the following conditions: one cycle of 3 min at 95°C, followed by 40 cycles of 95°C for 15 s and 72°C for 10 s After 40 cycles, a melting curve analysis was performed to detect the specific amplicons.
  • ICAM-1 CTTGAGGGCACCTACCTCTGTC CGGCTGTCTACCACAGTGATG
  • VCAM-1 ACACTTTATGTCAATGTTGCCCC GAGGCTGTAGCTCCCCGTTAG
  • Tubes containing (0.3 mL citrate solution/3 mL blood, 0.106 M CeHsNasO? x 2H2O, Sartstedt) were used to detect PMN elastase and TAT.
  • blood was collected in 2.7 mL CTAD tubes containing 270 pL of 0.109 M CTAD solution containing buffered sodium citrate, theophylline, adenosine and dipyridamole (BD Vacutainer CTAD, Becton-Dickinson GmbH, Heidelberg, Germany ), transferred and placed on ice for 15 minutes.
  • the EDTA and CTAD preparations were centrifuged at 2500 xg for 20 minutes at 4°C.
  • the citrated blood preparations were centrifuged at 1800 ⁇ g for 18 min at RT.
  • the blood plasma each Sample was snap frozen in liquid nitrogen and stored at -80°C until further investigation.
  • the numbers of erythrocytes, leukocytes and thrombocytes were measured in the collected blood samples with an automatic cell counting system (ABX Micros 60, HORIBA Medical, Minami-ku, Kyoto, Japan).
  • thrombin-antithrombin III complex TAT
  • sC5b-9 complement system
  • ß-thromboglobulin ß-thromboglobulin
  • neutrophils commercially available ELISA Kits (enzyme-linked immunosorbent assays) used according to manufacturer's instructions.
  • sC5b-9 (MicroVueTM Complement, Quidel Germany GmbH & AnDiaTec Division, Kornwestheim, Germany), TAT (Enzygnost® TAT micro, Siemens Healthcare, Er Weg, Germany), polymorphonuclear (PMN) elastase (Demeditec Diagnostics, Kiel, Germany) and ⁇ -TG (Asserachrom® ⁇ -TG, Diagnostica Stago, Parsippany, NJ, USA) ELISAs.
  • TAT Enzygnost® TAT micro, Siemens Healthcare, Er Weg, Germany
  • PMN polymorphonuclear
  • ⁇ -TG Assserachrom® ⁇ -TG, Diagnostica Stago, Parsippany, NJ, USA
  • Uncoated, DBCO-coated, or endothelialized HFMs were incubated with blood as described above. After incubating the HFMs with human blood for 90 minutes, the blood was collected and diluted 1:5 with DPBS. The samples were treated for 30 minutes at RT with 10 ⁇ l mouse anti-human CD41-FITC antibody (company) for the detection of platelets and 10 ⁇ l mouse anti-human CD62P-PE antibody (BD Biosciences, Heidelberg, Germany ) to detect platelets expressing P-selectin (CD62P), indicating platelet activation. Samples were fixed with 0.5% paraformaldehyde and platelet activation analyzed by flow cytometry. Scanning electron microscopy (SEM) analyzes of the HFM surfaces
  • HFMs were rinsed with 0.9% saline (Fresenius Kabi, Bad Homburg, Germany) and immersed in 2.5% glutaraldehyde (Sigma Aldrich, Darmstadt, Germany) fixed in DPBS. After the fixation step, the samples were washed with DPBS for 15 min at RT and then dehydrated in 15 min steps at RT with an ascending ethanol series (40%-100% ethanol; Merck-Millipore, Darmstadt, Germany).
  • 0.9% saline Fresenius Kabi, Bad Homburg, Germany
  • glutaraldehyde Sigma Aldrich, Darmstadt, Germany
  • Hydroxyl groups on the surface of materials can react with chemical groups on other molecules to form a covalent bond.
  • the free hydroxyl groups react with APTES.
  • Diluting APTES in anhydrous toluene is a widely used method in silanization.
  • the membranes were incubated for 30 min in 2% APTES (APTES, Sigma-Aldrich, Darmstadt) diluted in toluene (Sigma-Aldrich, Darmstadt, Germany) at 20 rpm and RT.
  • Three washing steps were then carried out in an ultrasonic bath for 2 min to remove unbound or weakly bound APTES.
  • DBCO Conjugation (Step 3 in Figure 1)
  • the silanized membranes were then diluted with 400 pM DBC0-PEG4-NHS ester (Jena Bioscience, Jena, Germany) in Dulbecco's phosphate-buffered saline (DPBS, Invitrogen) and incubated for 30 min at RT. After the incubation, three washing steps were carried out in DPBS for 5 min each.
  • the DBCO used contains a PEG4 chain to extend the DBCO to enable easier binding to the metabolically modified cells. Furthermore, there is an activated carboxylic acid (-NHS ester) on the DBCO used, which can react with amino groups from APTES and thus form covalent bonds.
  • the pressure was monitored with a pressure gauge (RS 1113, RS Components, Corby, UK) connected to the system.
  • the cells were washed with DPBS without Ca 2+ /Mg 2+ and with 5 pM DBCO-Sulfo-Cy3 (Jena Bioscience, Germany) in DPBS with Ca 2+ /Mg 2+ for 1 h at 37°C and 5% CO2 incubated.
  • the cells were then washed three times with 1 ml DPBS, detached with trypsin/EDTA (0.04%/0.03%) and centrifuged at 300 ⁇ g for 5 min.
  • the cell pellet was resuspended in 0.5 ml DPBS and the Cy3 labeling of 10,000 cells was analyzed by flow cytometry (FACS SCAN, BD, Heidelberg, Germany).
  • the HLIVECs were treated with 50 pM Ac4ManNAz for 48 hours. To determine if Na groups are present on the cell surface, cells were then incubated with 5 pM DBCO-Sulfo-Cy3 for 1 hour. The presence of N3 on the cell surface led to conjugation of DBCO and labeling of cells with Cy3 ( Figure 6A). The cells without Ac4ManNAz treatment were not stained. In addition, flow cytometric analyzes showed that about 98% of the cells analyzed were Cy3-positive (FIG. 6B). Treatment of the cells with Ac4ManNAz had no effect on the viability of the HUVECs ( Figure 6C).
  • DBCO-coated and uncoated HFMs were incubated with 5.2 x 10 6 Ac4ManNAz-labeled HUVECs for 24 hours under rotation and then for 24 hours under static conditions.
  • the attached HUVECs were detected by staining with calcein AM ( Figure 7A). Fluorescence microscopy analysis showed that Ac4ManNAz-treated HUVECs efficiently bound to the DBCO-functionalized HFM surface and resulted in almost complete endothelialization.
  • the detection of the fluorescence intensity of the HFMs also showed that the DBCO functionalization led to a significantly increased adhesion of the HUVECs compared to uncoated or APTES-coated HFMs (Figure 7B).
  • the tight cell-cell contacts of HUVECs on the HFM membranes were detected by staining with an anti-VE-cadherin antibody ( Figure 7C).
  • E-selectin The expression of the adhesion molecules E-selectin, VCAM-1 and ICAM-1 was analyzed after stimulation of the endothelial layer on HFMs with TNF- ⁇ and compared with the non-stimulated endothelial layer using qRT-PCR (Figure 8).
  • the stimulation of Endothelial layer with TNF- ⁇ resulted in significantly higher expression of E-selectin (199-fold), VCAM-1 (328-fold) and ICAM-1 (162-fold) compared to the unstimulated endothelial layer. This demonstrated the responsiveness of the generated endothelial layer to HFMs.
  • the P-selectin expression on the platelets was also analyzed as a marker for platelet activation. As shown in FIG. 9, a significantly higher number of activated platelets was detected on uncoated and DBCO-coated HFM compared to the blood samples without HFM. However, the endothelialized membranes prevented platelet activation.
  • thrombin-antithrombin III complex TAT
  • ⁇ -thromboglobulin a marker of platelet activation
  • the inventors provide a method by which biological cells can be covalently attached to surfaces in a very specific and selective manner. This enables efficient colonization of the surfaces, for example with endothelial cells, in order to prevent the surfaces from being recognized as "foreign".
  • the method can also be used to attach patient EPCs or "iPSC-derived" endothelial cells to desired surfaces of blood-contacting materials.
  • Off-the-shelf products can be manufactured that can be populated with the patient's own endothelial cells if required. The conjugation of the cells to the surface takes place without a catalyst under physiological conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de production d'une surface pouvant être peuplée de cellules biologiques, un dispositif présentant une surface qui peut être peuplée avec des cellules biologiques, et une méthode destinée à peupler une surface avec des cellules biologiques.
EP22768269.7A 2021-09-14 2022-08-16 Population de surfaces avec des cellules biologiques Pending EP4401803A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102021123779.3A DE102021123779A1 (de) 2021-09-14 2021-09-14 Besiedelung von Oberflächen mit biologischen Zellen
PCT/EP2022/072853 WO2023041275A1 (fr) 2021-09-14 2022-08-16 Population de surfaces avec des cellules biologiques

Publications (1)

Publication Number Publication Date
EP4401803A1 true EP4401803A1 (fr) 2024-07-24

Family

ID=83271222

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22768269.7A Pending EP4401803A1 (fr) 2021-09-14 2022-08-16 Population de surfaces avec des cellules biologiques

Country Status (7)

Country Link
US (1) US20240271104A1 (fr)
EP (1) EP4401803A1 (fr)
JP (1) JP2024535827A (fr)
KR (1) KR20240055861A (fr)
CA (1) CA3231506A1 (fr)
DE (1) DE102021123779A1 (fr)
WO (1) WO2023041275A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309660B1 (en) 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US11129926B2 (en) 2017-04-13 2021-09-28 Orbusneich Medical Pte. Ltd. Medical devices coated with polydopamine and antibodies
CN113795282A (zh) 2019-03-19 2021-12-14 杰美特涂层科技(厦门)有限公司 包含共价键合肝素涂层的医疗装置

Also Published As

Publication number Publication date
CA3231506A1 (fr) 2023-03-23
US20240271104A1 (en) 2024-08-15
WO2023041275A1 (fr) 2023-03-23
JP2024535827A (ja) 2024-10-02
DE102021123779A1 (de) 2023-03-16
KR20240055861A (ko) 2024-04-29

Similar Documents

Publication Publication Date Title
Subhedar et al. Nanocellulose in biomedical and biosensing applications: A review
Nakabayashi et al. Preparation of non-thrombogenic materials using 2-methacryloyloxyethyl phosphorylcholine
DE69214466T2 (de) Polymerbeschichtung
DE69932273T2 (de) Befestigung von Biomolekülen an Oberflächen von medizinischen Geräten
DE2812174C2 (de) Die Blutgerinnung nicht fördernde, biologisch verträgliche Gegenstände
EP0748633B1 (fr) Colle pour tissus à base de fibrinogène et son utilisation pour la préparation d'un hémostatique
CN102202771B (zh) 用于细胞扩增的辐照膜
DE69822872T2 (de) Verfahren zur oxidativen bindung von glycoproteinen und glycopeptiden an oberflächen von medizinischen artikeln
Dimitrievska et al. Glycocalyx‐Like Hydrogel Coatings for Small Diameter Vascular Grafts
DE10004884A1 (de) Verfahren zum Anbringen von Biomolekülen an Oberflächen mittels funktioneller Amin-Gruppen
CN107617126A (zh) 一种多孔材料的表面修饰方法及应用
CN103536958B (zh) 一种基于溶菌酶和丝蛋白的层层自组装改性纤维素纳米纤维膜及其制备与应用
CN103301506A (zh) 一种抗凝血丝素膜及其制备方法
Dai et al. Immobilizing argatroban and mPEG-NH2 on a polyethersulfone membrane surface to prepare an effective nonthrombogenic biointerface
WO1988003813A1 (fr) Procede pour la fabrication de substrats non thrombogenes
Raut et al. Engineering biomimetic polyurethane using polyethylene glycol and gelatin for blood-contacting applications
EP1152778B1 (fr) Surfaces hemocompatibles et procede permettant de les preparer
Liu et al. Electrofabrication of flexible and mechanically strong tubular chitosan implants for peripheral nerve regeneration
CN102477172B (zh) 壳聚糖-肝素纳米颗粒以及用该纳米颗粒处理的去细胞基质的生物材料
Peng et al. A robust mixed-charge zwitterionic polyurethane coating integrated with antibacterial and anticoagulant functions for interventional blood-contacting devices
Canjuga et al. Improving hemocompatibility of artificial lungs by click conjugation of glycoengineered endothelial cells onto blood-contacting surfaces
EP4401803A1 (fr) Population de surfaces avec des cellules biologiques
CN103272280A (zh) 一种对脱细胞血管支架或人造血管改性的方法
DE3026805C2 (fr)
EP2452624A1 (fr) Article théranostique implantable

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

17P Request for examination filed

Effective date: 20240409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR